Literature DB >> 35372851

Is There a Role for Device Therapies in Resistant Hypertension?: The CON Side.

Aldo J Peixoto1,2.   

Abstract

Entities:  

Keywords:  Baroreflex activation therapy; Blood Pressure; Clinical Nephrology; Hypertension; Resistant Hypertension; renal denervation

Mesh：

Year:  2020        PMID： 35372851      PMCID： PMC8808493          DOI： 10.34067/KID.0000742019

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  39 in total

1.  Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial.

Authors:  Uta C Hoppe; Mathias-Christoph Brandt; Rolf Wachter; Joachim Beige; Lars Christian Rump; Abraham A Kroon; Adam W Cates; Eric G Lovett; Hermann Haller
Journal:  J Am Soc Hypertens       Date:  2012-06-12

2.  Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis.

Authors:  Fadl Elmula M Fadl Elmula; Ying-Mei Feng; Lotte Jacobs; Anne C Larstorp; Sverre E Kjeldsen; Alexandre Persu; Jan A Staessen
Journal:  Blood Press       Date:  2017-04-26       Impact factor: 2.835

3.  Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study.

Authors:  Wilko Spiering; Bryan Williams; Jan Van der Heyden; Monique van Kleef; Rob Lo; Jorie Versmissen; Adriaan Moelker; Abraham Kroon; Hannes Reuter; Gary Ansel; Gregg W Stone; Mark Bates
Journal:  Lancet       Date:  2017-09-01       Impact factor: 79.321

4.  First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.

Authors:  Michael Böhm; Felix Mahfoud; Christian Ukena; Uta C Hoppe; Krzysztof Narkiewicz; Manuela Negoita; Luis Ruilope; Markus P Schlaich; Roland E Schmieder; Robert Whitbourn; Bryan Williams; Uwe Zeymer; Andreas Zirlik; Giuseppe Mancia
Journal:  Hypertension       Date:  2015-02-17       Impact factor: 10.190

5.  Effect of spironolactone on blood pressure in subjects with resistant hypertension.

Authors:  Neil Chapman; Joanna Dobson; Sarah Wilson; Björn Dahlöf; Peter S Sever; Hans Wedel; Neil R Poulter
Journal:  Hypertension       Date:  2007-02-19       Impact factor: 10.190

6.  Effectiveness of Renal Denervation in Resistant Hypertension: A Meta-Analysis of 11 Controlled Studies.

Authors:  Marco Pappaccogli; Michele Covella; Elena Berra; Chiara Fulcheri; Silvia Di Monaco; Elisa Perlo; Jacopo Burrello; Silvia Monticone; Denis Rossato; Franco Rabbia; Franco Veglio
Journal:  High Blood Press Cardiovasc Prev       Date:  2018-05-11

7.  Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.

Authors:  Enayet Karim Chowdhury; Christopher M Reid; Ella Zomer; Darren J Kelly; Danny Liew
Journal:  Am J Hypertens       Date:  2018-09-11       Impact factor: 2.689

8.  Refractory hypertension: definition, prevalence, and patient characteristics.

Authors:  Maria Czarina Acelajado; Roberto Pisoni; Tanja Dudenbostel; Louis J Dell'Italia; Falynn Cartmill; Bin Zhang; Stacey S Cofield; Suzanne Oparil; David A Calhoun
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-15       Impact factor: 3.738

9.  Renal Denervation for Resistant Hypertension in the contemporary era: A Systematic Review and Meta-analysis.

Authors:  Pradyumna Agasthi; Justin Shipman; Reza Arsanjani; Moses Ashukem; Marlene E Girardo; Charan Yerasi; Nithin R Venepally; Floyd David Fortuin; Farouk Mookadam
Journal:  Sci Rep       Date:  2019-04-17       Impact factor: 4.379

10.  Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.

Authors:  Raymond R Townsend; Felix Mahfoud; David E Kandzari; Kazuomi Kario; Stuart Pocock; Michael A Weber; Sebastian Ewen; Konstantinos Tsioufis; Dimitrios Tousoulis; Andrew S P Sharp; Anthony F Watkinson; Roland E Schmieder; Axel Schmid; James W Choi; Cara East; Anthony Walton; Ingrid Hopper; Debbie L Cohen; Robert Wilensky; David P Lee; Adrian Ma; Chandan M Devireddy; Janice P Lea; Philipp C Lurz; Karl Fengler; Justin Davies; Neil Chapman; Sidney A Cohen; Vanessa DeBruin; Martin Fahy; Denise E Jones; Martin Rothman; Michael Böhm
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.